Tratamiento con anticoagulantes orales: inicio, ajuste y precauciones en su utilización

Link, 1959, The discovery of dicumarol and its sequels, Circulation., 19, 97, 10.1161/01.CIR.19.1.97 Weiss, 1987, Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy, Thromb Res., 45, 783, 10.1016/0049-3848(87)90088-0 Ufer, 2005, Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocumarol, Clin Pharmacokinet., 44, 1227, 10.2165/00003088-200544120-00003 Pattacini, 1994, A comparative study of oral anticoagulant therapy (warfarin versus acenocumarol), Thromb Haemost., 71, 188 Barcellona, 1998, Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?, Thromb Haemost., 80, 899, 10.1055/s-0037-1615385 The International Warfarin Pharmacogenetics Consortium, 2009, Estimation of the warfarin dose with clinical and pharmacogenetic data, N Engl J Med, 360, 753, 10.1056/NEJMoa0809329 Bates, 1995, Incidence of adverse drug events. Implications for prevention. ADE Prevention Study Group, JAMA., 274, 29, 10.1001/jama.1995.03530010043033 Palareti, 2009, Bleeding with anticoagulation therapy -Who is at risk, and how best to identify such patients, Thromb Haemost., 102, 268 Hirsh, 1994, The international normalized ratio, Arch Intern Med., 154, 282, 10.1001/archinte.1994.00420030084008 Menéndez-Jándula, 2005, Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial, Ann Intern Med., 142, 1, 10.7326/0003-4819-142-1-200501040-00006 Harrison, 1997, Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy, Ann Intern Med., 126, 133, 10.7326/0003-4819-126-2-199701150-00006 James, 1992, Factors affecting the maintenance dose of warfarin, J Clin Pathol., 45, 704, 10.1136/jcp.45.8.704 Zevelin, 1993, Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors, J Clin Invest., 92, 2131, 10.1172/JCI116814 Gisbert, 1996, Drug therapy: management of venous thromboembolism, N Engl J Med., 335, 1816, 10.1056/NEJM199612123352407 Protocols per al control del tractament anticoagulant oral. Generalitat de Catalunya. Departament de Sanitat i Seguretat Social. 1998. Disponible en: http://www.gencat.cat/salut/depsalut/pdf/prottao.pdf Baglin, 2006, Guidelines on oral anticoagulation (warfarin): third edition-2005 update, Br J Haematol., 132, 277, 10.1111/j.1365-2141.2005.05856.x British Committee for Standards in Haematology, 1998, Guidelines on oral anticoagulation: third edition, Br J Haematol., 101, 374, 10.1046/j.1365-2141.1998.00715.x Ward, 2007, Dentoalveolar procedures for the anticoagulated patient: literature recommendations versus current practice, J Oral Maxillofac Surg., 65, 1454, 10.1016/j.joms.2007.03.003 Otley, 1996, Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs, Arch Dermatol., 132, 161, 10.1001/archderm.1996.03890260063009 Dunn, 2003, Perioperative management of patients receiving oral anticoagulants, Arch Intern Med., 163, 901, 10.1001/archinte.163.8.901 Yasaka, 2002, Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication, Thromb Res., 108, 25, 10.1016/S0049-3848(02)00402-4 Sanford, 2008, Dabigatran etexilate., Drugs., 68, 1699, 10.2165/00003495-200868120-00007 Eriksson, 2007, RE-NOVATE study group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double blind, non inferiority trial, Lancet., 370, 949, 10.1016/S0140-6736(07)61445-7 Eriksson, 2007, Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost., 5, 2178, 10.1111/j.1538-7836.2007.02748.x Connolly, 2009, RE-LY Steering Committee and Investigator. Dabigatran versus warfarina in patients with atrial fibrillation, N Engl J Med., 361, 1139, 10.1056/NEJMoa0905561 Eriksson, 2008, RECORD-1 study group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med., 358, 2765, 10.1056/NEJMoa0800374 Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med., 358, 2776, 10.1056/NEJMoa076016